EUCTR2017-000262-30-IT进行中（未招募）1 期
Efficacy, Safety, Tolerability and Pharmacokinetics of EXN-32 and EXN-44 in patients with Parkinson¿s Disease experiencing motor fluctuations - NA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Diagnosis of Idiopathic Parkinson’s Disease (according to modified Hoehn and Yahr Criteria Stages I - IV) (may allow stage IV in and ON” period).
- •¿ Patients’ receiving stable regimen of levodopa for at least one month before screening with or without concomitant therapy with dopamine agonists, COMT inhibitors, MAO-B inhibitors, or amantadine.
- •¿ Patient suffering from at least three OFF” periods on an average per day for last one months (including one in the morning).
- •¿ Subjects, male and female, aged 40 years or higher.
- •¿ Provide written informed consent.
- •¿ Be willing and able to comply with the study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •¿ Atypical or secondary Parkinsonism.
- •¿ Lack of response to levodopa.
- •¿ Any dopamine receptor-blocking agent or non-selective MAO inhibitors.
- •¿ Dyskinesia disability score > 3 from UPDRS.
- •¿ Previous stereotactic surgery.
- •¿ Any participation in a clinical trial in the previous 6 months.
- •¿ Current or previous (within last 12 months) history of alcohol or substance abuse.
- •¿ Malignant melanoma or suspicious undiagnosed skin lesion.
- •¿ Narrow-angle glaucoma.
- •¿ Hypersensitivity to levodopa.
- •¿ Myocardial infarction with residual problems, abnormal kidney function, or abnormal liver transaminase values.
- •Contraception requirements (in case of female subjects of child bearing potential):
- •Females must either be postmenopausal with no menses for at least 12 months or surgically sterile (hysterectomy or tubal ligation) or agree to use a highly effective method of contraception with a pearl index of <1% up to 1 month after last dose. Contraception methods with low user dependency should preferably be used, in particular when
- •contraception is introduced as a result of participation in this clinical study. Highly effective’ methods of birth control include*:
- •¿ combined (estrogen and progesterone containing) hormonal contraception associated with inhibition of ovulation:
- •o intravaginal
- •o transdermal
- •¿ progesterone-only hormonal contraception associated with inhibition of ovulation*:
- •o injectable
- •o implantable†
- •¿ intra-uterine device (IUD)†
- •¿ intra-uterine hormone releasing system (IUS)†
- •¿ bilateral tubular occlusion†
- •¿ vasectomy of sexual partner that was performed at least 90 days prior to Baseline, and has been medically assessed as successful†
- •¿ sexual abstinence
- •o Note: Sexually inactive female subjects may be enrolled at the investigator’s discretion provided that they are counselled to refrain from heterosexual intercourse for the duration of the study and for one month after the last dose, and understand the possible risks involved in getting pregnant during the study.
- •*Hormonal methods: If on hormonal contraceptives, must have been on the same hormonal contraceptive product for 3 months (90 days) prior to Baseline
- •and continued on same method and dose throughout the duration of the study.
- •If subject had used hormonal birth control and had stopped, this should have occurred more than 6 months prior to Baseline. Female subjects on low dose oral contraceptives (containing =35 µg of ethinyl estradiol or equivalent dose of other estrogens) must use a second form of contraceptive during the study.
- •†Contraception methods that are considered to have low user dependency.
研究者
相似试验
进行中（未招募）
不适用
Efficacy, safety, tolerability and pharmacokinetics of concomitant administration of tramadol with duloxetine or pregabalin: a randomized controlled flexible-dose study in patients with neuropathic paiG53.0 Vyöruusun jälkeinen hermosärkyG63.2 Diabeteksen monihermosairausMedDRA version: 9.1Level: LLTClassification code 10036377Term: Postherpetic polyneuropathyMedDRA version: 9.1Level: LLTClassification code 10012680Term: Diabetic neuropathyEUCTR2009-013061-26-FIniversity of Turku40
招募中
3 期
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With systemic juvenile idiopathic arthritis (sJIA)CTRI/2022/03/040770Pfizer Inc
招募中
不适用
Safety, tolerability, efficacy and pharmacokinetic study of increasing doses of B26826 in adult patients with known or suspected intracranial lesions referred for contrast-enhanced MRI of the brain.Intracraniële laesies verwezen voor contrastverbeterde MRI van de hersenencontrast mediumintracranial lesionsNL-OMON54381Bracco Imaging S.pA.12
进行中（未招募）
不适用
Pharmacokinetics, efficacy, tolerability and safety evaluation of the therapy with subcutaneous immunoglobulin in the treatment of hypo or agammaglobulinaemic patients. Open label phase II/III study - NDHypogammaglobulinaemia or agammaglobulinaemiaMedDRA version: 9.1Level: LLTClassification code 10060384MedDRA version: 9.1Level: LLTClassification code 10001471EUCTR2010-020167-20-ITKEDRIO
进行中（未招募）
1 期
Efficacy and Safety Study Of Tofacitinib in Pediatric sJIA PopulatioSystemic Juvenile Idiopathic Arthritis (sJIA)EUCTR2017-002018-29-ITPFIZER INC100